Annexon Biosciences(ANNX)
$3.57-0.35 (-8.93%)
ANNX
Annexon Biosciences financials statements
$3.57
At close:-0.35 (-8.93%)
Want to see ANNX full AI Analyst Report?
Annexon Biosciences (ANNX) Ratios
1,429 Followers
Annexon Biosciences Ratios
ANNX's free cash flow for Q3 2026 was $-48.68M. For the 2026 fiscal year, ANNX's free cash flow was increased by $0.00 and operating cash flow was $-48.68M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.68 | 10.37 | 14.72 | 11.10 | 11.39 |
| Quick Ratio | 5.68 | 10.37 | 14.72 | 11.10 | 11.39 |
| Cash Ratio | 3.80 | 1.62 | 12.56 | 6.26 | 3.44 |
| Solvency Ratio | -3.10 | -2.37 | -2.80 | -2.59 | -2.33 |
| Operating Cash Flow Ratio | -4.37 | -3.87 | -6.76 | -5.20 | -4.88 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 176.27M | $ 259.50M | $ 216.74M | $ 194.20M | $ 192.56M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.09 | 0.08 | 0.11 | 0.12 | 0.12 |
| Debt-to-Equity Ratio | 0.12 | 0.10 | 0.13 | 0.14 | 0.15 |
| Debt-to-Capital Ratio | 0.11 | 0.09 | 0.11 | 0.12 | 0.13 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.31 | 1.19 | 1.19 | 1.23 | 1.24 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.17 | 0.21 | 0.41 | 0.60 | 0.90 |
| Net Debt to EBITDA | 0.66 | 0.15 | 1.37 | 0.75 | 0.31 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 95.51% | 89.70% | 93.40% | 97.49% | 99.70% |
| Return on Assets (ROA) | -74.46% | -39.48% | -45.10% | -49.79% | -45.40% |
| Return on Equity (ROE) | -97.66% | -47.15% | -53.58% | -61.40% | -56.20% |
| Return on Capital Employed (ROCE) | -92.11% | -48.21% | -51.38% | -55.42% | -49.27% |
| Return on Invested Capital (ROIC) | -90.99% | -47.84% | -50.98% | -55.14% | -49.05% |
| Return on Tangible Assets | -74.46% | -39.48% | -45.10% | -49.79% | -45.40% |
| Earnings Yield | -26.55% | -19.61% | -39.07% | -50.22% | -29.60% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.25 | 0.33 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1478.52 | -1101.76 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 1478.52 | 1101.76 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.20 | -0.86 | -1.60 | -2.13 | -2.77 |
| Free Cash Flow Per Share | -1.20 | -0.86 | -1.60 | -2.25 | -2.81 |
| Dividend Paid and CapEx Coverage Ratio | -1360.26 | -7867.07 | -627.68 | -17.82 | -64.15 |
| Capital Expenditure Coverage Ratio | -1360.26 | -7867.07 | -627.68 | -17.82 | -64.15 |
| Operating Cash Flow Coverage Ratio | -7.11 | -4.07 | -3.86 | -3.54 | -3.07 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -23.95% | -16.74% | -35.32% | -43.46% | -24.48% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.75 | -5.10 | -2.56 | -1.99 | -3.38 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 3.68 | 2.40 | 1.37 | 1.22 | 1.90 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.18 | -5.97 | -2.83 | -2.30 | -4.09 |
| Price-to-Operating Cash Flow Ratio | -4.18 | -5.97 | -2.84 | -2.43 | -4.15 |
| Price-to-Earnings Growth (PEG) Ratio | -0.11 | 0.12 | 0.08 | 0.09 | 0.35 |
| Enterprise Value Multiple | -3.14 | -5.08 | -1.06 | -1.22 | -3.11 |
| Enterprise Value | 642.78M | 684.36M | 149.80M | 175.50M | 400.00M |
| EV to EBITDA | -3.14 | -5.08 | -1.06 | -1.22 | -3.11 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -3.45 | -5.80 | -1.23 | -1.43 | -3.71 |
| EV to Operating Cash Flow | -3.45 | -5.80 | -1.24 | -1.51 | -3.77 |
| Tangible Book Value Per Share | 1.36 | 2.13 | 3.31 | 4.23 | 6.05 |
| Shareholders’ Equity Per Share | 1.36 | 2.13 | 3.31 | 4.23 | 6.05 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.33 | -1.01 | -1.77 | -2.60 | -3.40 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.93 | 0.97 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.90 | 0.85 | 0.90 | 0.82 | 0.81 |
Currency in USD

